Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases

Chuan-Zhuo Wang; Guang-Xin Yan; He Xin; Zhao-Yu Liu

doi:10.4251/wjgo.v12.i9.1044

Oncological outcomes and predictors of radiofrequency ablation of colorectal cancer liver metastases

World J Gastrointest Oncol. 2020 Sep 15;12(9):1044-1055. doi: 10.4251/wjgo.v12.i9.1044.

Authors

Chuan-Zhuo Wang¹, Guang-Xin Yan¹, He Xin¹, Zhao-Yu Liu²

Affiliations

¹ Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China.
² Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China. liushjh@163.com.

Abstract

Background: Surgical resection is considered the standard treatment option for long-term survival in colorectal cancer liver metastasis (CRLM) patients, but only a small number of patients are suitable for resection following diagnosis. Radiofrequency ablation (RFA) is an accepted alternative therapy for CRLM patients who are not suitable for resection. However, the relatively high rate of local tumor progression (LTP) is an obstacle to the more widespread use of RFA.

Aim: To determine the oncological outcomes and predictors of RFA in CRLM patients.

Methods: A retrospective analyze was performed on the clinical data of 85 consecutive CRLM patients with a combined total of 138 liver metastases, who had received percutaneous RFA treatment at our institution from January 2013 to December 2018. Contrast-enhanced computed tomography was performed the first month after RFA to assess the technique effectiveness of the RFA and to serve as a baseline for subsequent evaluations. The Kaplan-Meier method was used to calculate overall survival (OS) and LTP-free survival (LTPFS). The log-rank test and Cox regression model were used for univariate and multivariate analyses to determine the predictors of the oncological outcomes.

Results: There were no RFA procedure-related deaths, and the technique effectiveness of the treatment was 89.1% (123/138). The median follow-up time was 30 mo. The LTP rate was 32.6% (45/138), and the median OS was 36 mo. The 1-, 3-, and 5-year OS rates were 90.6%, 45.6%, and 22.9%, respectively. Univariate analysis revealed that tumor size and ablative margin were the factors influencing LTPFS, while extrahepatic disease (EHD), tumor number, and tumor size were the factors influencing OS. Multivariate analysis showed that tumor size larger than 3 cm and ablative margin of 5 mm or smaller were the independent predictors of shorter LTPFS, while tumor number greater than 1, size larger than 3 cm, and presence of EHD were the independent predictors of shorter OS.

Conclusion: RFA is a safe and effective treatment method for CRLM. Tumor size and ablative margin are the important factors affecting LTPFS. Tumor number, tumor size, and EHD are also critical factors for OS.

Keywords: Colorectal cancer liver metastasis; Local tumor progression; Local tumor progression-free survival; Overall survival; Radiofrequency ablation.